
Opinion|Videos|December 22, 2023
Updates in Lower-Risk MDS: Imetelstat
Author(s)Yazan Madanat, MD
Yazan Madanat, MD, comments on the updates that were recently presented at ASH 2023 for the management of lower-risk MDS and discusses the impact of emerging therapies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5














































